Home > Publications database > Early bilirubinemia after allogeneic stem cell transplantation-an endothelial complication. > print

001     167287
005     20240229133535.0
024 7 _ |a 10.1038/s41409-020-01186-6
|2 doi
024 7 _ |a pmid:33517355
|2 pmid
024 7 _ |a 0268-3369
|2 ISSN
024 7 _ |a 0951-3078
|2 ISSN
024 7 _ |a 1476-5365
|2 ISSN
024 7 _ |a altmetric:99258159
|2 altmetric
037 _ _ |a DKFZ-2021-00242
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Dai, Hao
|0 P:(DE-He78)e1550b77d7eed3425c8e245362b45281
|b 0
|e First author
245 _ _ |a Early bilirubinemia after allogeneic stem cell transplantation-an endothelial complication.
260 _ _ |a London
|c 2021
|b Nature Publishing Group55086
264 _ 1 |3 online
|2 Crossref
|b Springer Science and Business Media LLC
|c 2021-01-30
264 _ 1 |3 print
|2 Crossref
|b Springer Science and Business Media LLC
|c 2021-07-01
264 _ 1 |3 print
|2 Crossref
|b Springer Science and Business Media LLC
|c 2021-07-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1626252116_16039
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:C020# / 2021 Jul;56(7):1573-1583
520 _ _ |a Hyperbilirubinemia occurs frequently after allogeneic stem cell transplantation. Causes include primary liver damage and endothelial complications as major contributors. Here, we have investigated the impact of early bilirubinemia (EB) on posttransplant outcomes. Maximum total bilirubin levels (days 0-28) were categorized using maximally selected log rank statistics to identify a cut off for the endpoint non-relapse mortality (NRM) in a training cohort of 873 patients. EB above this cut off was correlated with NRM and overall survival (OS) and with pre- and posttransplant Angiopoietin-2, interleukin (IL)18, CXCL8 and suppressor of tumorigenicity-2 (ST2) serum levels, and the endothelial activation and stress index (EASIX). Clinical correlations were validated in a sample of 388 patients transplanted in an independent institution. The EB cut off was determined at 3.6 mg/dL (61.6 µM). EB predicted OS (HR 1.60, 95% CI 1.21-2.12, p < 0.001), and NRM (CSHR 2.14; 1.28-3.56, p = 0.004), also independent of typical endothelial complications such as veno-occlusive disease, refractory acute graft-versus-host disease, or transplant-associated microangiopathy. However, EB correlated with high Angiopoietin-2, EASIX-pre and EASIX-day 0, as well as increased levels of posttransplant CXCL8, IL18, and ST2. In summary, EB indicates a poor prognosis. The association of EB with endothelial biomarkers suggests an endothelial pathomechanism also for this posttransplant complication.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|x 0
|f POF IV
542 _ _ |i 2021-01-30
|2 Crossref
|u https://creativecommons.org/licenses/by/4.0
542 _ _ |i 2021-01-30
|2 Crossref
|u https://creativecommons.org/licenses/by/4.0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Penack, Olaf
|b 1
700 1 _ |a Radujkovic, Aleksandar
|b 2
700 1 _ |a Schult, David
|b 3
700 1 _ |a Majer-Lauterbach, Joshua
|b 4
700 1 _ |a Blau, Igor Wolfgang
|b 5
700 1 _ |a Bullinger, Lars
|b 6
700 1 _ |a Jiang, Sihe
|b 7
700 1 _ |a Müller-Tidow, Carsten
|b 8
700 1 _ |a Dreger, Peter
|0 0000-0002-7429-8570
|b 9
700 1 _ |a Luft, Thomas
|b 10
773 1 8 |a 10.1038/s41409-020-01186-6
|b Springer Science and Business Media LLC
|d 2021-01-30
|n 7
|p 1573-1583
|3 journal-article
|2 Crossref
|t Bone Marrow Transplantation
|v 56
|y 2021
|x 0268-3369
773 _ _ |a 10.1038/s41409-020-01186-6
|0 PERI:(DE-600)2004030-1
|n 7
|p 1573-1583
|t Bone marrow transplantation
|v 56
|y 2021
|x 0268-3369
909 C O |o oai:inrepo02.dkfz.de:167287
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)e1550b77d7eed3425c8e245362b45281
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BONE MARROW TRANSPL : 2014
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED
999 C 5 |a 10.1111/joim.12854
|9 -- missing cx lookup --
|1 J Canaani
|p 407 -
|2 Crossref
|u Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji RM, et al. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. J Intern Med. 2019;285:407–18.
|t J Intern Med.
|v 285
|y 2019
999 C 5 |a 10.1056/NEJMoa1004383
|9 -- missing cx lookup --
|1 TA Gooley
|p 2091 -
|2 Crossref
|u Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.
|t N Engl J Med.
|v 363
|y 2010
999 C 5 |a 10.1007/s13770-018-0157-3
|9 -- missing cx lookup --
|1 S Kanagasundram
|p 1 -
|2 Crossref
|u Kanagasundram S, Amini F. Late complications of allogenic stem cells transplantation in leukaemia. Tissue Eng Regen Med. 2019;16:1–9.
|t Tissue Eng Regen Med
|v 16
|y 2019
999 C 5 |a 10.1182/bloodadvances.2019032268
|9 -- missing cx lookup --
|1 R Shouval
|p 1881 -
|2 Crossref
|u Shouval R, Fein JA, Shouval A, Danylesko I, Shem-Tov N, Zlotnik M, et al. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019;3:1881–90.
|t Blood Adv.
|v 3
|y 2019
999 C 5 |a 10.3389/fmicb.2018.02795
|9 -- missing cx lookup --
|1 AB Versluys
|p 2795 -
|2 Crossref
|u Versluys AB, Boelens JJ. Morbidity and mortality associated with respiratory virus infections in allogeneic hematopoietic cell transplant: too little defense or harmful immunity? Front Microbiol. 2018;9:2795.
|t Front Microbiol.
|v 9
|y 2018
999 C 5 |a 10.1182/blood-2017-05-782870
|9 -- missing cx lookup --
|1 NJ Gloude
|p 1259 -
|2 Crossref
|u Gloude NJ, Khandelwal P, Luebbering N, Lounder DT, Jodele S, Alder MN, et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood. 2017;130:1259–66.
|t Blood.
|v 130
|y 2017
999 C 5 |a 10.2215/CJN.10630917
|9 -- missing cx lookup --
|1 S Hingorani
|p 866 -
|2 Crossref
|u Hingorani S, Pao E, Stevenson P, Schoch G, Laskin BL, Gooley T, et al. Changes in glomerular filtration rate and impact on long-term survival among adults after hematopoietic cell transplantation: a prospective cohort study. Clin J Am Soc Nephrology. 2018;13:866–73.
|t Clin J Am Soc Nephrology.
|v 13
|y 2018
999 C 5 |a 10.1182/blood-2011-02-334821
|9 -- missing cx lookup --
|1 T Luft
|p 1685 -
|2 Crossref
|u Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A, et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood. 2011;118:1685–92.
|t Blood.
|v 118
|y 2011
999 C 5 |a 10.1038/bmt.2017.121
|9 -- missing cx lookup --
|1 E Mir
|p 1317 -
|2 Crossref
|u Mir E, Palomo M, Rovira M, Pereira A, Escolar G, Penack O, et al. Endothelial damage is aggravated in acute GvHD and could predict its development. Bone Marrow Transplant. 2017;52:1317–25.
|t Bone Marrow Transplant.
|v 52
|y 2017
999 C 5 |a 10.1182/bloodadvances.2019000143
|9 -- missing cx lookup --
|1 S Pagliuca
|p 2424 -
|2 Crossref
|u Pagliuca S, Michonneau D, Sicre de Fontbrune F, Sutra Del Galy A, Xhaard A, Robin M, et al. Allogeneic reactivity-mediated endothelial cell complications after HSCT: a plea for consensual definitions. Blood Adv. 2019;3:2424–35.
|t Blood Adv.
|v 3
|y 2019
999 C 5 |a 10.1016/j.bbmt.2018.04.024
|9 -- missing cx lookup --
|1 E Pao
|p 1678 -
|2 Crossref
|u Pao E, Gove NE, Flynn JT, Hingorani S. Ambulatory blood pressure and endothelial dysfunction in hematopoietic cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24:1678–84.
|t Biol Blood Marrow Transplant
|v 24
|y 2018
999 C 5 |a 10.1016/j.bbmt.2018.07.031
|9 -- missing cx lookup --
|1 C Rondon-Clavo
|p 2517 -
|2 Crossref
|u Rondon-Clavo C, Scordo M, Hilden P, Shah GL, Cho C, Maloy MA, et al. Early fluid overload is associated with an increased risk of nonrelapse mortality after ex vivo CD34-selected allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018;24:2517–22.
|t Biol Blood Marrow Transplant.
|v 24
|y 2018
999 C 5 |a 10.2174/0929867324666171012110244
|9 -- missing cx lookup --
|1 A Ruggeri
|p 4535 -
|2 Crossref
|u Ruggeri A, Paviglianiti A, Volt F, Kenzey C, Rafii H, Rocha V, et al. Endothelial and circulating progenitor cells in hematological diseases and allogeneic hematopoietic stem cell transplantation. Curr Med Chem. 2018;25:4535–44.
|t Curr Med Chem.
|v 25
|y 2018
999 C 5 |a 10.1111/petr.13269
|9 -- missing cx lookup --
|1 S Yamamoto
|p e13269 -
|2 Crossref
|u Yamamoto S, Toyama D, Sugishita Y, Kaneko R, Okamoto N, Koganesawa M, et al. Prophylactic recombinant thrombomodulin treatment prevents hepatic sinusoidal obstruction syndrome in high-risk pediatric patients that undergo hematopoietic stem cell transplants. Pediatr Transplant. 2018;22:e13269.
|t Pediatr Transplant.
|v 22
|y 2018
999 C 5 |a 10.1038/bmt.2017.119
|9 -- missing cx lookup --
|1 M Zeisbrich
|p 1399 -
|2 Crossref
|u Zeisbrich M, Becker N, Benner A, Radujkovic A, Schmitt K, Beimler J, et al. Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant. 2017;52:1399–405.
|t Bone Marrow Transplant
|v 52
|y 2017
999 C 5 |a 10.1016/j.bbmt.2012.09.018
|9 -- missing cx lookup --
|1 S Dietrich
|p 22 -
|2 Crossref
|u Dietrich S, Falk CS, Benner A, Karamustafa S, Hahn E, Andrulis M, et al. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol Blood Marrow Transplant. 2013;19:22–7.
|t Biol Blood Marrow Transplant
|v 19
|y 2013
999 C 5 |a 10.1016/j.bbmt.2016.05.018
|9 -- missing cx lookup --
|1 S Tatekawa
|p 1573 -
|2 Crossref
|u Tatekawa S, Kohno A, Ozeki K, Watamoto K, Ueda N, Yamaguchi Y, et al. A novel diagnostic and prognostic biomarker panel for endothelial cell damage-related complications in allogeneic transplantation. Biol Blood Marrow Transplant. 2016;22:1573–81.
|t Biol Blood Marrow Transplant.
|v 22
|y 2016
999 C 5 |a 10.1016/j.bbmt.2014.04.030
|9 -- missing cx lookup --
|1 N Ueda
|p 1335 -
|2 Crossref
|u Ueda N, Chihara D, Kohno A, Tatekawa S, Ozeki K, Watamoto K, et al. Predictive value of circulating angiopoietin-2 for endothelial damage-related complications in allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1335–40.
|t Biol Blood Marrow Transplant.
|v 20
|y 2014
999 C 5 |a 10.1016/j.bbmt.2005.06.001
|9 -- missing cx lookup --
|1 VT Ho
|p 571 -
|2 Crossref
|u Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:571–5.
|t Biol Blood Marrow Transplant
|v 11
|y 2005
999 C 5 |a 10.1182/blood-2014-03-564997
|9 -- missing cx lookup --
|1 S Jodele
|p 645 -
|2 Crossref
|u Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124:645–53.
|t Blood.
|v 124
|y 2014
999 C 5 |a 10.1097/00007890-198712000-00011
|9 -- missing cx lookup --
|1 RJ Jones
|p 778 -
|2 Crossref
|u Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778–83.
|t Transplantation.
|v 44
|y 1987
999 C 5 |a 10.3324/haematol.10699
|9 -- missing cx lookup --
|1 T Ruutu
|p 95 -
|2 Crossref
|u Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92:95–100.
|t Haematologica.
|v 92
|y 2007
999 C 5 |1 HM Shulman
|y 1992
|2 Crossref
|u Shulman HM, Hinterberger W. Hepatic veno-occlusive disease–liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant. 1992;10:197–214.
999 C 5 |a 10.1016/S2352-3026(17)30108-4
|9 -- missing cx lookup --
|1 T Luft
|p e414 -
|2 Crossref
|u Luft T, Benner A, Jodele S, Dandoy CE, Storb R, Gooley T, et al. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol. 2017;4:e414–23.
|t Lancet Haematol.
|v 4
|y 2017
999 C 5 |a 10.1038/s41409-019-0703-1
|9 -- missing cx lookup --
|1 T Luft
|p 553 -
|2 Crossref
|u Luft T, Benner A, Terzer T, Jodele S, Dandoy CE, Storb R, et al. EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplant. 2020;55:553–61.
|t Bone Marrow Transplant
|v 55
|y 2020
999 C 5 |a 10.1038/s41409-019-0634-x
|9 -- missing cx lookup --
|1 T Konuma
|p 2096 -
|2 Crossref
|u Konuma T, Oiwa-Monna M, Mizusawa M, Isobe M, Kato S, Takahashi S, et al. Early fluid overload predicts higher non-relapse and overall mortality in adults after single-unit cord blood transplantation. Bone Marrow Transplant. 2019;54:2096–101.
|t Bone Marrow Transplant
|v 54
|y 2019
999 C 5 |a 10.1016/j.bbmt.2017.08.021
|9 -- missing cx lookup --
|1 G Rondon
|p 2166 -
|2 Crossref
|u Rondon G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, et al. Impact of fluid overload as new toxicity category on hematopoietic stem cell transplantation outcomes. Biol Blood Marrow Transplant. 2017;23:2166–71.
|t Biol Blood Marrow Transplant.
|v 23
|y 2017
999 C 5 |a 10.1053/j.seminhematol.2011.10.001
|9 -- missing cx lookup --
|1 A Rovo
|p 25 -
|2 Crossref
|u Rovo A, Tichelli A. Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Cardiovascular complications in long-term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2012;49:25–34.
|t Semin Hematol
|v 49
|y 2012
999 C 5 |1 DK Cheuk
|y 2015
|2 Crossref
|u Cheuk DK, Chiang AK, Ha SY, Chan GC. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2015;5:CD009311.
999 C 5 |a 10.1097/00007890-197410000-00001
|9 -- missing cx lookup --
|1 H Glucksberg
|p 295 -
|2 Crossref
|u Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
|t Transplantation.
|v 18
|y 1974
999 C 5 |a 10.1038/bmt.2016.130
|9 -- missing cx lookup --
|1 M Mohty
|p 906 -
|2 Crossref
|u Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51:906–12.
|t Bone Marrow Transplant
|v 51
|y 2016
999 C 5 |a 10.3324/haematol.2019.238790
|9 -- missing cx lookup --
|2 Crossref
|u Jiang S, Penack O, Terzer T, Schult D, Majer-Lauterbach J, Radujkovic A, et al. Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel. Haematologica. 2020. https://doi.org/10.3324/haematol.2019.238790. Online ahead of print.
999 C 5 |a 10.1016/j.bbmt.2009.07.004
|9 -- missing cx lookup --
|1 A Bacigalupo
|p 1628 -
|2 Crossref
|u Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.
|t Biol Blood Marrow Transplant
|v 15
|y 2009
999 C 5 |a 10.1016/S1470-2045(12)70349-2
|9 -- missing cx lookup --
|1 M Bornhauser
|p 1035 -
|2 Crossref
|u Bornhauser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13:1035–44.
|t Lancet Oncol.
|v 13
|y 2012
999 C 5 |a 10.1016/j.bbmt.2018.06.013
|9 -- missing cx lookup --
|1 C Strouse
|p 2072 -
|2 Crossref
|u Strouse C, Zhang Y, Zhang MJ, DiGilio A, Pasquini M, Horowitz MM, et al. Risk score for the development of veno-occlusive disease after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transplant. 2018;24:2072–80.
|t Biol Blood Marrow Transplant.
|v 24
|y 2018
999 C 5 |2 Crossref
|u [Internet]. VRC. Center for International Blood & Marrow Transplant Research. 2018. https://www.cibmtr.org/ReferenceCenter/Statistical/Tools/Pages/VOD.aspx.
999 C 5 |a 10.1007/s00180-015-0582-x
|9 -- missing cx lookup --
|1 S-y Woo
|p 369 -
|2 Crossref
|u Woo S-y, Kim S, Kim J. Determining cutoff values of prognostic factors in survival data with competing risks. Comput Stat. 2015;31:369–86.
|t Comput Stat.
|v 31
|y 2015
999 C 5 |2 Crossref
|u Holländer N, Sauerbrei W, Schumacher M Estimating the effect of a prognostic or risk factor after selection of an “Optimal” Cutpoint. 2001. http://www.fdm.uni-freiburg.de/publications-preprints/papers/pre73.pdf.
999 C 5 |a 10.1038/bmt.2012.130
|9 -- missing cx lookup --
|1 M Ashizawa
|p 94 -
|2 Crossref
|u Ashizawa M, Oshima K, Wada H, Ishihara Y, Kawamura K, Sakamoto K, et al. Hyperbilirubinemia in the early phase after allogeneic HSCT: prognostic significance of the alkaline phosphatase/total bilirubin ratio. Bone Marrow Transplant. 2013;48:94–8.
|t Bone Marrow Transplant.
|v 48
|y 2013
999 C 5 |a 10.1038/bmt.2012.25
|9 -- missing cx lookup --
|1 P Barba
|p 1343 -
|2 Crossref
|u Barba P, Martino R, Perez-Simon JA, Fernandez-Aviles F, Pinana JL, Valcarcel D, et al. Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2012;47:1343–9.
|t Bone Marrow Transplant
|v 47
|y 2012
999 C 5 |a 10.1016/j.bbmt.2011.04.009
|9 -- missing cx lookup --
|1 P Barba
|p 1653 -
|2 Crossref
|u Barba P, Pinana JL, Fernandez-Aviles F, Perez-Simon JA, Martino R, Lopez-Guerrero E, et al. Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients. Biol Blood Marrow Transplant. 2011;17:1653–61.
|t Biol Blood Marrow Transplant
|v 17
|y 2011
999 C 5 |a 10.1002/hep.20529
|9 -- missing cx lookup --
|1 TA Gooley
|p 345 -
|2 Crossref
|u Gooley TA, Rajvanshi P, Schoch HG, McDonald GB. Serum bilirubin levels and mortality after myeloablative allogeneic hematopoietic cell transplantation. Hepatology. 2005;41:345–52.
|t Hepatology.
|v 41
|y 2005
999 C 5 |a 10.1161/01.RES.0000255690.03436.ae
|9 -- missing cx lookup --
|1 WC Aird
|p 174 -
|2 Crossref
|u Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res. 2007;100:174–90.
|t Circ Res.
|v 100
|y 2007
999 C 5 |a 10.1161/01.RES.0000255691.76142.4a
|9 -- missing cx lookup --
|1 WC Aird
|p 158 -
|2 Crossref
|u Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007;100:158–73.
|t Circ Res.
|v 100
|y 2007
999 C 5 |a 10.1073/pnas.1912409116
|9 -- missing cx lookup --
|1 ACA Cleuren
|p 23618 -
|2 Crossref
|u Cleuren ACA, van der Ent MA, Jiang H, Hunker KL, Yee A, Siemieniak DR, et al. The in vivo endothelial cell translatome is highly heterogeneous across vascular beds. Proc Natl Acad Sci USA. 2019;116:23618–24.
|t Proc Natl Acad Sci USA
|v 116
|y 2019
999 C 5 |a 10.1007/s00277-016-2758-z
|9 -- missing cx lookup --
|1 M Ecsedi
|p 1627 -
|2 Crossref
|u Ecsedi M, Schmohl J, Zeiser R, Drexler B, Halter J, Medinger M, et al. Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. 2016;95:1627–36.
|t Ann Hematol
|v 95
|y 2016
999 C 5 |a 10.1038/nm1351
|9 -- missing cx lookup --
|1 U Fiedler
|p 235 -
|2 Crossref
|u Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235–9.
|t Nat Med.
|v 12
|y 2006
999 C 5 |a 10.1080/07853890701779586
|9 -- missing cx lookup --
|1 JV Patel
|p 215 -
|2 Crossref
|u Patel JV, Lim HS, Varughese GI, Hughes EA, Lip GY. Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension. Ann Med. 2008;40:215–22.
|t Ann Med.
|v 40
|y 2008
999 C 5 |a 10.1038/bmt.2012.101
|9 -- missing cx lookup --
|1 M Porkholm
|p 50 -
|2 Crossref
|u Porkholm M, Bono P, Saarinen-Pihkala UM, Kivivuori SM. Higher angiopoietin-2 and VEGF levels predict shorter EFS and increased non-relapse mortality after pediatric hematopoietic SCT. Bone Marrow Transplant. 2013;48:50–5.
|t Bone Marrow Transplant.
|v 48
|y 2013
999 C 5 |a 10.1016/j.cardfail.2012.01.008
|9 -- missing cx lookup --
|1 SJ Aldous
|p 304 -
|2 Crossref
|u Aldous SJ, Richards AM, Troughton R, Than M. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail. 2012;18:304–10.
|t J Card Fail.
|v 18
|y 2012
999 C 5 |a 10.1056/NEJMc1700185
|9 -- missing cx lookup --
|1 SJ Rotz
|p 1189 -
|2 Crossref
|u Rotz SJ, Dandoy CE, Davies SM. ST2 and endothelial injury as a Link between GVHD and microangiopathy. N Engl J Med. 2017;376:1189–90.
|t N Engl J Med.
|v 376
|y 2017
999 C 5 |a 10.1056/NEJMoa1213299
|9 -- missing cx lookup --
|1 MT Vander Lugt
|p 529 -
|2 Crossref
|u Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, et al. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013;369:529–39.
|t N Engl J Med.
|v 369
|y 2013
999 C 5 |a 10.1002/clc.23274
|9 -- missing cx lookup --
|1 A Akerblom
|p 1202 -
|2 Crossref
|u Akerblom A, James SK, Lakic TG, Becker RC, Cannon CP, Steg PG, et al. Interleukin-18 in patients with acute coronary syndromes. Clin Cardiol. 2019;42:1202–9.
|t Clin Cardiol
|v 42
|y 2019
999 C 5 |a 10.1016/j.ebiom.2019.10.024
|9 -- missing cx lookup --
|1 A Radujkovic
|p 202 -
|2 Crossref
|u Radujkovic A, Kordelas L, Dai H, Schult D, Majer-Lauterbach J, Beelen D, et al. Interleukin-18 and outcome after allogeneic stem cell transplantation: a retrospective cohort study. EBioMedicine. 2019;49:202–12.
|t EBioMedicine.
|v 49
|y 2019
999 C 5 |a 10.1016/j.bbmt.2018.12.105
|9 -- missing cx lookup --
|1 RM Saliba
|p S32 -
|2 Crossref
|u Saliba RM, Rondon G, Chen J, Ledesma C, Champlin RE, Ciurea SO. Endothelial Activation and Stress Index (EASIX) is associated with fluid overload and survival in recipients of allogeneic stem cell transplantation. Biol Blood Bone Marrow Transplant. 2019;25:S32–3.
|t Biol Blood Bone Marrow Transplant.
|v 25
|y 2019

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21